Early diagnostic potential of &lt;em&gt;APC &lt;/em&gt;hypermethylation in esophageal cancer

Wang, Bujiang; Song, Haoming; Jiang, Haizhong; Fu, Yangbo; Ding, Xiaoyun; Zhou, Chongchang

doi:10.2147/cmar.s148677

Cited by 8 publications

(7 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 3 The prognosis of ESCC is poor, and patients have only 15%–25% of 5-year survival rates after diagnosis. 4 – 6 …”

Section: Introductionmentioning

confidence: 99%

Profiles of differentially expressed circRNAs in esophageal and breast cancer

Shi¹,

Sun²,

He³

et al. 2018

CMAR

View full text Add to dashboard Cite

IntroductionCircular RNAs (circRNAs) function as efficient microRNA sponges with gene-regulatory potential and are promising cancer biomarkers. In this study, we used the Arraystar Human circRNA Array to construct a genome-wide circRNA profile of esophageal squamous cell cancer (ESCC) and breast cancer (BC).Patients and methodsExpression levels between cancer lesions and adjacent normal-appearing tissues were compared. We observed 469 upregulated circRNAs and 275 downregulated circRNAs in ESCC. Hsa_circRNA_103670 was upregulated 20.3-fold, while hsa_circRNA_030162 was downregulated 12.1-fold. For BC, 715 circRNAs were upregulated, and 440 circRNAs were downregulated. Hsa_circRNA_005230 was upregulated 12.2-fold, while hsa_circRNA_406225 was downregulated 12.4-fold.ResultsWhen we set the criteria as fold change in expression ≥2 between cancer and adjacent normal-appearing tissue with a P-value <0.01, there were 22 common circRNAs (11 upregulated and 11 downregulated) in relation to both ESCC and BC. Gene ontology and the Kyoto encyclopedia of genes and genomes analyses showed that these circRNAs were involved in the tumorigenesis of human cancers.ConclusionOur study revealed that circRNAs are promising candidates as valuable biomarkers for ESCC and BC, although relevant research is still in its infancy and the functional role of specific circRNAs in tumorigenesis is just starting to be elucidated.

show abstract

“… 3 The prognosis of ESCC is poor, and patients have only 15%–25% of 5-year survival rates after diagnosis. 4 – 6 …”

Section: Introductionmentioning

confidence: 99%

Profiles of differentially expressed circRNAs in esophageal and breast cancer

Shi¹,

Sun²,

He³

et al. 2018

CMAR

View full text Add to dashboard Cite

show abstract

“…At the same time, a significant increase in methylation was observed in correlation with tumor grade [ 20 ]. Similarly, in another study from 2018, a significant relationship was shown between esophageal cancer and APC promoter gene methylation [ 21 , 22 ]. In another meta-analysis of 2018, 2483 patients and 1218 controls from 31 studies were evaluated and the relationship between breast cancer and APC gene methylation was studied.…”

Section: Discussionmentioning

confidence: 84%

What are the roles of global DNA and APC 2 gene promotor hypermethylation in multiple myeloma?

et al. 2021

View full text Add to dashboard Cite

Background In today's practice, gene-based approaches come to the fore in the determination of prognosis and treatment preferences of multiple myeloma (MM). DNA methylation is one of the new approach parameters. DNA methylation occurs by the addition of a methyl group to cytosines in CpG dinucleotides. In this study, besides comparing the global DNA and APC 2 gene promotor hypermethylation between our patients with MM and healthy control group, we aimed to demonstrate the effect of hypermethylation on MM treatment responses and survival. Methods and results 38 patients diagnosed with MM between January 2016 and January 2020 and 50 healthy controls were included in the study. The initial hypermethylation of the patients and the healthy control group were statistically analyzed. In addition, the increase in hypermethylation in the MM group before and after the first series of treatments were analyzed within themselves. There is a significant difference between the patients with MM diagnosis and the healthy control group in terms of the initial global hypermethylation (P = 0.001). In patients with MM, hypermethylation was significantly higher. Global hypermethylation in the post-treatment measurements was significantly increased in comparison to the pre-treatment state (P = 0.012). In terms of APC 2 promotor gene-specific hypermethylation, no significant differences were detected between pre- and post-treatment values (P = 0.368). Conclusions This study represents valuable data with the initial global DNA hypermethylation results in the MM patient group and the increase in hypermethylation post-treatment. it will shed light on future studies.

show abstract

“…There was also a direct association between APC promoter hyper methylation and grade of tumor differentiation [ 57 ]. The Chinese esophageal cancer tumors had also higher rates of APC methylation compared with controls [ 171 ]. SFRP2 is one of the negative regulators of WNT signaling pathway.…”

Section: Signaling Pathwaysmentioning

confidence: 99%

Methylation as a critical epigenetic process during tumor progressions among Iranian population: an overview

et al. 2021

View full text Add to dashboard Cite

Cancer is one of the main health challenges and leading causes of deaths in the world. Various environmental and genetic risk factors are associated with tumorigenesis. Epigenetic deregulations are also important risk factors during tumor progression which are reversible transcriptional alterations without any genomic changes. Various mechanisms are involved in epigenetic regulations such as DNA methylation, chromatin modifications, and noncoding RNAs. Cancer incidence and mortality have a growing trend during last decades among Iranian population which are significantly related to the late diagnosis. Therefore, it is required to prepare efficient molecular diagnostic panels for the early detection of cancer in this population. Promoter hyper methylation is frequently observed as an inhibitory molecular mechanism in various genes associated with DNA repair, cell cycle regulation, and apoptosis during tumor progression. Since aberrant promoter methylations have critical roles in early stages of neoplastic transformations, in present review we have summarized all of the aberrant methylations which have been reported during tumor progression among Iranian cancer patients. Aberrant promoter methylations are targetable and prepare novel therapeutic options for the personalized medicine in cancer patients. This review paves the way to introduce a non-invasive methylation specific panel of diagnostic markers for the early detection of cancer among Iranians.

show abstract

Early diagnostic potential of <em>APC </em>hypermethylation in esophageal cancer

Cited by 8 publications

References 43 publications

Profiles of differentially expressed circRNAs in esophageal and breast cancer

Profiles of differentially expressed circRNAs in esophageal and breast cancer

What are the roles of global DNA and APC 2 gene promotor hypermethylation in multiple myeloma?

Methylation as a critical epigenetic process during tumor progressions among Iranian population: an overview

Contact Info

Product

Resources

About